Business Wire10.24.18
QST Consultations Ltd. has appointed Dr. Phil Doren as CEO and a member of the Board of Directors. Dr. John Quiring, who founded the company, has been operating as interim CEO since January. He will continue to provide strategic advice to clients as chief scientific officer and guidance to the company as board chairman.
“It is an honor to join QST and build upon the strong foundation that exists,” said Doren. “As a mature organization committed to high quality in clinical research, I look forward to enhancing the existing culture and business structure as we continue to diversify our therapeutic expertise and build on our current service offerings. John has done a tremendous job at fostering the entrepreneurial spirit which is well established and rooted in honesty, integrity, ethics and quality in all aspects of the business.”
Doren joins the executive leadership team at QST with over 25 years of experience in developing and managing partnerships in the clinical research industry. His most recent position was president, Frontage Clinical Services, where he led early phase clinical research and pharmacometrics. Prior to Frontage Clinical Services, Doren was the general manager and vice president of Clinical Operations at Everest Clinical Research; global vice president of Biometrics at SynteractHCR; vice president, Clinical Data Analysis and Reporting Organization at Covance; and vice president, head of Biostatistics – North America at Quintiles. Additionally, he held executive positions at eRT, TKL Research, and Kendle. Doren received his bachelor of science degree from the University of Minnesota, and his master of science degree and doctor of philosophy from Texas A&M University.
In July, Veronica Powell was promoted to the executive team as chief operating officer. Powell's leadership and other contributions to QST became increasingly apparent during this year as Quiring assumed the interim-CEO role. “I'm confident in her fit for the role and ability to provide the proper support to the CEO that will enable QST as an organization to reach new heights. I hold in high esteem Veronica's determination, organization and creative thinking for resolving issues and look forward to her continued contributions to our leadership team as COO,” Quiring said.
According to Quiring, “QST Consultations builds meaningful, consultative, long-lasting relationships with our clients. We strive to exceed expectations and provide the highest possible quality clinical development services available to the clinical research industry. QST is responsive to client’s needs through persistent attention to detail and demonstrated leadership in overcoming development challenges. We are proud of what we have accomplished and confident that the solid leadership team will increase our success and the success of our clients.”
QST Consultations is a full service clinical research organization dedicated to providing specialized clinical research support for the pharmaceutical and medical device industries since its founding in 1974 (incorporation in 1985). QST specializes in clinical study design, protocol development including statistical methodology, clinical operations, data management, biostatistical analysis, report writing, and U.S. Food and Drug Administration consultation.
“It is an honor to join QST and build upon the strong foundation that exists,” said Doren. “As a mature organization committed to high quality in clinical research, I look forward to enhancing the existing culture and business structure as we continue to diversify our therapeutic expertise and build on our current service offerings. John has done a tremendous job at fostering the entrepreneurial spirit which is well established and rooted in honesty, integrity, ethics and quality in all aspects of the business.”
Doren joins the executive leadership team at QST with over 25 years of experience in developing and managing partnerships in the clinical research industry. His most recent position was president, Frontage Clinical Services, where he led early phase clinical research and pharmacometrics. Prior to Frontage Clinical Services, Doren was the general manager and vice president of Clinical Operations at Everest Clinical Research; global vice president of Biometrics at SynteractHCR; vice president, Clinical Data Analysis and Reporting Organization at Covance; and vice president, head of Biostatistics – North America at Quintiles. Additionally, he held executive positions at eRT, TKL Research, and Kendle. Doren received his bachelor of science degree from the University of Minnesota, and his master of science degree and doctor of philosophy from Texas A&M University.
In July, Veronica Powell was promoted to the executive team as chief operating officer. Powell's leadership and other contributions to QST became increasingly apparent during this year as Quiring assumed the interim-CEO role. “I'm confident in her fit for the role and ability to provide the proper support to the CEO that will enable QST as an organization to reach new heights. I hold in high esteem Veronica's determination, organization and creative thinking for resolving issues and look forward to her continued contributions to our leadership team as COO,” Quiring said.
According to Quiring, “QST Consultations builds meaningful, consultative, long-lasting relationships with our clients. We strive to exceed expectations and provide the highest possible quality clinical development services available to the clinical research industry. QST is responsive to client’s needs through persistent attention to detail and demonstrated leadership in overcoming development challenges. We are proud of what we have accomplished and confident that the solid leadership team will increase our success and the success of our clients.”
QST Consultations is a full service clinical research organization dedicated to providing specialized clinical research support for the pharmaceutical and medical device industries since its founding in 1974 (incorporation in 1985). QST specializes in clinical study design, protocol development including statistical methodology, clinical operations, data management, biostatistical analysis, report writing, and U.S. Food and Drug Administration consultation.
